- This is “a longitudinal observational matched cohort study to assess differences in HCRU and estimated costs within 30 days after infusion for patients (pts) receiving commercial cilta-cel in the OP setting (prospective observational arm) compared to IP administration (retrospective matched cohort).”
- “The pts receiving OP cilta-cel consented for this IRB-approved pilot study and were provided with noninvasive TempTraq® axillary patches for high-frequency temperature monitoring”
- “Pts in the OP cohort were hospitalized for significantly less time (5 vs 10 days; p = <0.001).”
- “OP treatment significantly reduced the median length of inpatient stay by five days and led to a meaningful reduction in the estimated median post-infusion cost by $19,180 per patient”
Cost-conscious CAR T delivery: Outpatient (OP) cilta-cel administration reduces health care resource utilization (HCRU) and the associated post-infusion cost
MD Anderson